成人IgA血管炎的疾病负担与死亡率:长期人群队列研究
该研究基于澳大利亚西部州级链接健康数据,纳入1980至2015年住院成人IgA血管炎患者267例及匹配对照1080例,随访19年。结果显示IgA血管炎患者死亡率显著高于对照(MRR=2.06)及一般人群(SMRR=5.64),合并症指数、肾衰竭和既往严重感染为独立死亡风险因素。
要点
- 住院成人IgA血管炎患者长期死亡率显著高于匹配对照和一般人群。
- 诊断前合并症负担更重、严重感染风险更高,且感染相关死亡更常见。
- 合并症指数、肾衰竭和既往严重感染是独立死亡风险因素。
核心结论
- 住院成人IgA血管炎患者病前合并症积累增加,并预测过早死亡。
- 合并症不能完全解释病前感染风险增加或感染所致死亡率增加,需前瞻性研究。
研究设计与样本
- 观察性人群队列研究,使用州级链接纵向健康数据,纳入1980至2015年住院成人IgA血管炎患者267例及匹配对照1080例。
- 记录诊断前广泛回看期内的Charlson合并症指数和严重感染,从西澳大利亚死亡登记处提取死亡日期和原因。
- 评估死亡率(死亡/1000人年)比值和生存风险比。
主要发现
- 回看期9.9(9.8)年间,IgA血管炎患者Charlson合并症指数评分更高(2.60 vs 1.50,P < 0.001),严重感染风险更高(OR = 8.4,P < 0.001),且不能完全由合并症指数解释。
- 随访19年间,IgA血管炎患者死亡137例,对照死亡397例,死亡率比值MRR = 2.06(95% CI: 1.70-2.50;P < 0.01),标准化死亡率比值SMRR = 5.64(95% CI: 4.25, 7.53;P < 0.001)。
- IgA血管炎患者5年生存率72.7% vs 89.7%,20年生存率45.2% vs 65.6%(均P < 0.05)。
- Charlson合并症指数(HR = 1.88,95% CI: 1.25, 2.73;P = 0.001)、肾衰竭(HR = 1.48,95% CI: 1.04, 2.22;P = 0.03)和既往严重感染(HR = 1.48,95% CI: 1.01, 2.16;P = 0.04)为独立风险因素。
- IgA血管炎患者感染所致死亡更常见(5.8% vs 1.8%,P = 0.02)。
临床怎么用
- 对住院成人IgA血管炎患者应评估诊断前合并症负担和既往严重感染史,以识别死亡高风险个体。
- 关注肾衰竭和感染预防,可能有助于改善长期生存。
局限性
- 观察性研究,不能完全排除残余混杂。
- 仅纳入住院成人患者,结论可能不适用于非住院或儿童患者。
- 合并症不能完全解释感染风险和感染相关死亡增加,机制需前瞻性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: With sparse data available, we investigated mortality and risk factors in adults with IgA vasculitis (IgAV). METHODS: This was an observational population-based cohort study using state-wide linked longitudinal health data for hospitalized adults with IgAV (n = 267) and matched comparators (n = 1080) between 1980 and 2015. Charlson comorbidity index (CCI) and serious infections (SIs) were recorded over an extensive lookback period prior to diagnosis. Date and causes of death were extracted from the Western Australia Death Registry. Mortality rate (deaths/1000 person-years) ratios (MRRs) and hazard ratio (HR) for survival were assessed. RESULTS: During 9.9 (9.8) years lookback patients with IgAV accrued higher CCI scores (2.60 vs 1.50, P < 0.001) and had higher risk of SI (OR = 8.4, P < 0.001), not fully explained by CCI scores. During 19 years' follow-up, the rate of death in patients with IgAV (n = 137) was higher than in comparators (n = 397) (MRR = 2.06, 95% CI: 1.70-2.50; P < 0.01) and the general population (standardized mortality rate ratio = 5.64, 95% CI: 4.25, 7.53; P < 0.001). Survival in IgAV was reduced at 5 (72.7 vs 89.7%) and 20 years (45.2% vs 65.6%) (both P < 0.05). CCI (HR = 1.88, 95% CI: 1.25, 2.73; P = 0.001), renal failure (HR = 1.48, 95% CI: 1.04, 2.22; P = 0.03) and prior SI (HR = 1.48, 95% CI: 1.01, 2.16; P = 0.04) were independent risk factors. Death from infections (5.8 vs 1.8%, P = 0.02) was significantly more frequent in patients with IgAV. CONCLUSION: Premorbid comorbidity accrual appears increased in hospitalized patients with IgAV and predicts premature death. As comorbidity does not fully explain the increased risk of premorbid infections or the increased mortality due to infections in IgAV, prospective studies are needed.
引用
- Nossent J, Raymond W, Isobel Keen H, et al. Morbidity and mortality in adult-onset IgA vasculitis: a long-term population-based cohort study. Rheumatology (Oxford). 2021. PMID: 33779729. doi:10.1093/rheumatology/keab312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。